Mizuho Securities USA (MSUSA), the US investment subsidiary of Mizuho Financial Group (NYSE: MFG), has named Irina Koffler as its newest Managing Director and Senior Analyst, according to an MSUSA statement.
In her new role as MSUSA’s Managing Director & Senior Analyst, Ms. Koffler will focus on leading the group’s specialty pharmaceutical research.
According to John Koudounis, President and CEO, in a recent statement on the appointment, “Irina comes to us with extensive pharma expertise, both as an analyst and gained directly in the industry. She is indicative of the caliber of senior talent we have added as we continue to expand our US Equity Research team.”
Is it Time For Banks to Move Over And Create Space For Blockchain?Go to article >>
“We are building a premier US equity research franchise that is a leader in original, value-added investment ideas and analysis. We are very pleased to welcome Irina to the firm,” he added.
Ms. Koffler joins MSUSA from Cantor Fitzgerald, having served in a similar role across its specialty pharmaceuticals business. Prior to Cantor, she also served as the Senior Vice President (SVP) and senior research analyst for specialty pharmaceuticals at Duncan-Williams.
“Irina’s experience and depth of industry knowledge will enhance our equity research presence in the US and complement our global research product. She will be an invaluable addition to the firm,” noted Matthew DeSalvo, Executive Managing Director and Head of MSUSA’s Equity Division, in an accompanying statement.
Back in May, MSUSA augmented its US equity team with two senior appointments, including Patrick Moran and Richard Telesco, both having joined MSUSA as position traders.